TW202328125A - Bcl-2抑制劑的固體形式、製備方法及其用途 - Google Patents
Bcl-2抑制劑的固體形式、製備方法及其用途 Download PDFInfo
- Publication number
- TW202328125A TW202328125A TW111132850A TW111132850A TW202328125A TW 202328125 A TW202328125 A TW 202328125A TW 111132850 A TW111132850 A TW 111132850A TW 111132850 A TW111132850 A TW 111132850A TW 202328125 A TW202328125 A TW 202328125A
- Authority
- TW
- Taiwan
- Prior art keywords
- crystalline form
- compound
- ray powder
- powder diffraction
- crystalline
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 239000007787 solid Substances 0.000 title claims abstract description 26
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract description 5
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 32
- 230000008569 process Effects 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 229940125904 compound 1 Drugs 0.000 claims description 245
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 226
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 69
- 238000010438 heat treatment Methods 0.000 claims description 52
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 41
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 38
- 239000012453 solvate Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 25
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 23
- 239000013078 crystal Substances 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 235000019439 ethyl acetate Nutrition 0.000 claims description 20
- 238000001816 cooling Methods 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims description 11
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- -1 7-azaspiro[3.5]nonan-7-yl Chemical group 0.000 claims description 7
- 239000011877 solvent mixture Substances 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 230000009477 glass transition Effects 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 230000002885 thrombogenetic effect Effects 0.000 claims 1
- 238000002411 thermogravimetry Methods 0.000 description 66
- 238000005481 NMR spectroscopy Methods 0.000 description 41
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 39
- 230000004580 weight loss Effects 0.000 description 38
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 26
- 238000001228 spectrum Methods 0.000 description 21
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000000354 decomposition reaction Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 239000012535 impurity Substances 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000002425 crystallisation Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000861 pro-apoptotic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003331 prothrombotic effect Effects 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000006624 extrinsic pathway Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000004441 surface measurement Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- KWYNXIYNKOCJPK-HKBQPEDESA-N 4-[2-[(2S)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoic acid Chemical compound N1C=CC=2C1=NC=C(C=2)OC1=C(C(=O)O)C=CC(=C1)N1CCC2(CC(C2)N2[C@@H](CCC2)C2=C(C=CC=C2)C(C)C)CC1 KWYNXIYNKOCJPK-HKBQPEDESA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000004072 Oncogene Addiction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040483 Sexual inhibition Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000000373 single-crystal X-ray diffraction data Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/CN2021/115718 | 2021-08-31 | ||
| CN2021115718 | 2021-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202328125A true TW202328125A (zh) | 2023-07-16 |
Family
ID=85410866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111132850A TW202328125A (zh) | 2021-08-31 | 2022-08-31 | Bcl-2抑制劑的固體形式、製備方法及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317743A1 (https=) |
| EP (1) | EP4396180A4 (https=) |
| JP (1) | JP2024530315A (https=) |
| KR (1) | KR20240054327A (https=) |
| CN (1) | CN118215660A (https=) |
| AU (1) | AU2022336557A1 (https=) |
| CA (1) | CA3230314A1 (https=) |
| IL (1) | IL311106A (https=) |
| MX (1) | MX2024002465A (https=) |
| TW (1) | TW202328125A (https=) |
| WO (1) | WO2023030363A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296582A (en) | 2020-04-15 | 2022-11-01 | Beigene Ltd | bcl-2 inhibitor |
| WO2026002056A1 (en) | 2024-06-26 | 2026-01-02 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138588A2 (en) * | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2668180B1 (en) * | 2011-01-25 | 2018-08-01 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer |
| SG11202009933WA (en) * | 2018-04-29 | 2020-11-27 | Beigene Ltd | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-08-31 EP EP22863498.6A patent/EP4396180A4/en active Pending
- 2022-08-31 JP JP2024513277A patent/JP2024530315A/ja active Pending
- 2022-08-31 CA CA3230314A patent/CA3230314A1/en active Pending
- 2022-08-31 AU AU2022336557A patent/AU2022336557A1/en active Pending
- 2022-08-31 WO PCT/CN2022/116084 patent/WO2023030363A1/en not_active Ceased
- 2022-08-31 MX MX2024002465A patent/MX2024002465A/es unknown
- 2022-08-31 CN CN202280058535.7A patent/CN118215660A/zh active Pending
- 2022-08-31 IL IL311106A patent/IL311106A/en unknown
- 2022-08-31 TW TW111132850A patent/TW202328125A/zh unknown
- 2022-08-31 KR KR1020247010341A patent/KR20240054327A/ko active Pending
-
2024
- 2024-02-27 US US18/589,022 patent/US20240317743A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024530315A (ja) | 2024-08-16 |
| WO2023030363A1 (en) | 2023-03-09 |
| CA3230314A1 (en) | 2023-03-09 |
| KR20240054327A (ko) | 2024-04-25 |
| CN118215660A (zh) | 2024-06-18 |
| AU2022336557A1 (en) | 2024-03-21 |
| EP4396180A4 (en) | 2025-07-09 |
| EP4396180A1 (en) | 2024-07-10 |
| US20240317743A1 (en) | 2024-09-26 |
| IL311106A (en) | 2024-04-01 |
| MX2024002465A (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105001165B (zh) | 取代的二氨基嘧啶其组合物，和用其治疗的方法 | |
| US10023577B2 (en) | Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof | |
| KR20210013554A (ko) | Tlr7/tlr8 억제제의 결정질 형태 | |
| ES2985767T3 (es) | Formas en estado sólido de rucaparib y de sales de rucaparib | |
| AU2015330554B2 (en) | Crystal form of bisulfate of JAK inhibitor and preparation method therefor | |
| US20240317743A1 (en) | Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof | |
| JP2025538506A (ja) | がんの治療のための縮合ピリジンの固体形態 | |
| JP2018516946A (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
| TW202404604A (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| EP4222148A1 (en) | Crystalline form of tegavivint, method of preparation, and use thereof | |
| EP2262786A2 (en) | Colchicine solid-state forms; methods of making; and methods of use thereof | |
| JP2022546861A (ja) | マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用 | |
| CN114026088A (zh) | Jak2抑制剂的结晶形式 | |
| HK40106793A (zh) | Bcl-2抑制剂的固体形式、其制备方法及用途 | |
| EP3327007A1 (en) | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | |
| US10344041B2 (en) | Polymorphic forms and co-crystals of a c-Met inhibitor | |
| CN111499627A (zh) | 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型 | |
| TW202400595A (zh) | ５Ｈ－吡咯并［２，３－ｂ］吡𠯤衍生物的多晶形式、製備方法及其用途 | |
| WO2022224269A1 (en) | Co-crystals, salts and solid forms of niraparib | |
| HK40116055A (zh) | 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式 | |
| JP2024525472A (ja) | Ｓｃｏ－１０１の熱力学的に安定な型 | |
| WO2025130951A1 (zh) | Ad-35多晶型物及其制备方法和用途 | |
| HK40095644A (zh) | 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途 | |
| CZ2015758A3 (cs) | Pevné formy vápenaté soli ethyl esteru (2R, 4S)-5-(bifenyl-4-yl)-4-[(3-karboxypropionyl)amino]-2-methylpentanové kyseliny, způsob jejich přípravy a použití |